Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of enpatoran for active cutaneous lupus erythematosus with or without systemic lupus erythematosus
CTR20261950Phase 3Active
- Sponsor
- Merck KGaA
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enpatoran in cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), sponsored by Merck KGaA. Started Sep 2026; status: active.
02
Drugs
enpatoran
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20261950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261950.